Acute non-lymphocytic leukemia (ANLL) following treatment with dacarbazine for malignant melanoma.
ANLL followed a brief period of aplastic anemia in a man treated intensively 4 years and 3 months previously with dacarbazine as "adjuvant" therapy for malignant melanoma. This is the first reported instance in which the latency between drug exposure and onset of leukemia strongly implicates dacarbazine as a leukemogenic agent.
D000208:Acute Disease; D003606:Dacarbazine / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D007938:Leukemia / Q000139:chemically induced*; D008297:Male; D008545:Melanoma / Q000188:drug therapy*; D008875:Middle Aged; D009113:Muramidase / Q000097:blood; D012535:Scalp; D012878:Skin Neoplasms / Q000188:drug therapy*
D003606:Dacarbazine; D009113:Muramidase